<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H16C23D62E57B4A2FB1FC60001C86438B" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 1227 IH: Alternatives to Prevent Addiction In the Nation Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-02-12</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1227</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250212">February 12, 2025</action-date><action-desc><sponsor name-id="M001215">Mrs. Miller-Meeks</sponsor> (for herself, <cosponsor name-id="B001300">Ms. Barragán</cosponsor>, <cosponsor name-id="K000376">Mr. Kelly of Pennsylvania</cosponsor>, and <cosponsor name-id="P000613">Mr. Panetta</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend title XVIII of the Social Security Act to ensure appropriate access to non-opioid pain management drugs under part D of the Medicare program.</official-title></form><legis-body id="H5F8A834FA4D24410AB6512ED451CEA62" style="OLC"><section id="HA79D450465C841C0AADB99E450A0A98A" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Alternatives to Prevent Addiction In the Nation Act</short-title></quote> or the <quote><short-title>Alternatives to PAIN Act</short-title></quote>. </text></section><section id="H27F34D677EB84D75BF456D339DDAD336"><enum>2.</enum><header>Appropriate cost-sharing for qualifying non-opioid pain management drugs under medicare part D</header><subsection id="H5F024A3FC128438D813F68D7889285B3"><enum>(a)</enum><header>Medicare part d</header><text>Section 1860D–2 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-102">42 U.S.C. 1395w–102</external-xref>) is amended—</text><paragraph id="HC938B13DDBEB47549A240BC18399EBFB"><enum>(1)</enum><text>in subsection (b)—</text><subparagraph id="H10B57CEB786C4C2AA6FB144CFDC3DFC1"><enum>(A)</enum><text>in paragraph (1)(A), in the matter preceding clause (i), by striking <quote>paragraphs (8) and (9)</quote> and inserting <quote>paragraphs (8), (9), and (10)</quote>;</text></subparagraph><subparagraph id="H2AC501D8E8C14FD68DAD080A79CAC308"><enum>(B)</enum><text display-inline="yes-display-inline">in paragraph (2)(A), in the matter preceding clause (i), in subparagraph (A), by striking <quote>paragraphs (8) and (9)</quote> and inserting <quote>paragraphs (8), (9), and (10)</quote>; and</text></subparagraph><subparagraph id="H30556CEA07BB4A0B9DE7B930EC557F7A"><enum>(C)</enum><text>by adding at the end the following new paragraph:</text><quoted-block id="H4B5C53C9E3F9436894FD201B411D6B71" style="OLC"><paragraph id="H8BEBFA41053B4712A2559471A31F1B2A"><enum>(10)</enum><header>Treatment of cost-sharing for qualifying non-opioid pain management drugs</header><subparagraph id="HA95EE36A911140A9B1E8645BAA0E56B3"><enum>(A)</enum><header>In general</header><text>For plan years beginning on or after January 1, 2026, with respect to a covered part D drug that is a qualifying non-opioid pain management drug (as defined in subparagraph (B))—</text><clause id="HA48C8404579E488DA0DD5FD21CB4499D"><enum>(i)</enum><text>the deductible under paragraph (1) shall not apply; and</text></clause><clause id="H27D7E2B9E44D42E0814E10DF50DDEFBA"><enum>(ii)</enum><text>such drug shall be placed on the lowest cost-sharing tier, if any, for purposes of determining the maximum co-insurance or other cost-sharing for such drug.</text></clause></subparagraph><subparagraph id="H2024FBF8FAE7429E821D7F67732DD9A6"><enum>(B)</enum><header>Qualifying non-opioid pain management drugs</header><text>In this paragraph, the term <quote>qualifying non-opioid pain management drug</quote> means a drug or biological product—</text><clause id="H448E201A3BCA470F877433FD510242E8"><enum>(i)</enum><text>that has a label indication approved by the Food and Drug Administration to reduce postoperative pain or any other form of acute pain;</text></clause><clause id="H3AAA8C24384E43D68B4130D8A0E24F5C"><enum>(ii)</enum><text>that does not act upon the body’s opioid receptors;</text></clause><clause id="H736518BE882646EBBE0D0ECC19F01D96"><enum>(iii)</enum><text>for which there is no other drug or product that is—</text><subclause id="HEA6DDE1EADD441C2ACE90614A3FC063C"><enum>(I)</enum><text>rated as therapeutically equivalent (under the Food and Drug Administration’s most recent publication of <quote>Approved Drug Products with Therapeutic Equivalence Evaluations</quote>); and</text></subclause><subclause id="H382D6E16158745E9B7152AE6553C47AC"><enum>(II)</enum><text>sold or marketed in the United States; and</text></subclause></clause><clause id="H52750D93BA424665936F8A76D58428A4"><enum>(iv)</enum><text>for which the wholesale acquisition cost (as defined in section 1847A(c)(6)(B)), for a monthly supply does not exceed the monthly specialty-tier cost threshold as determined by the Secretary from time to time.</text></clause></subparagraph></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="H195415D3311244EE89FA5B91989B7456"><enum>(2)</enum><text>in subsection (c), by adding at the end the following new paragraph:</text><quoted-block id="H89D36E626F60404B95A753DA761B4119" style="OLC"><paragraph id="HCB4E0ABA170749FC8A6AA47B563272EF"><enum>(7)</enum><header>Treatment of cost-sharing for qualifying non-opioid pain management drugs</header><text>The coverage is provided in accordance with subsection (b)(10).</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H883EA7B2564B40CF9D002E5A2FCBC6E1"><enum>(b)</enum><header>Conforming amendments to cost-Sharing for low-Income individuals</header><text>Section 1860D–14(a) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-114">42 U.S.C. 1395w–114(a)</external-xref>) is amended—</text><paragraph id="HDBB7F4ED66CD4401B0E8DFAD82B99443"><enum>(1)</enum><text>in paragraph (1)(D), in each of the clauses (ii) and (iii), by striking <quote>Subject to paragraph (6)</quote> and inserting <quote>Subject to paragraphs (6) and (7)</quote>; and</text></paragraph><paragraph id="H4CC9CB6D8342408B9C719C99A3E18C82"><enum>(2)</enum><text>by adding at the end the following new paragraph:</text><quoted-block id="H3CB8DFC828C94F8C948E0F2B0243B825" style="OLC"><paragraph id="HF9FE0E2BA6C549C0B8C62A15C86BE8A0"><enum>(7)</enum><header>Treatment of cost-sharing or deductible for qualifying non-opioid pain management drugs</header><text>For plan years beginning on or after January 1, 2026, with respect to a covered part D drug that is a qualifying non-opioid pain management drug (as defined in section 1860D–2(b)(10)(B))—</text><subparagraph id="H1BB5A442F06248B0903FB05B232A20C0"><enum>(A)</enum><text>the deductible under section 1860D-2(b)(1) shall not apply; and</text></subparagraph><subparagraph id="H4DE0F394CF0A47E6A96DF710944798B8"><enum>(B)</enum><text>such drug shall be placed on the lowest cost-sharing tier, if any, for purposes of determining the maximum co-insurance or other cost-sharing for such drug.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection></section><section id="HC3AF42C0AD654D7EA1E7FE6263BF96A0"><enum>3.</enum><header>Prohibition on the use of step therapy and prior authorization for qualifying non-opioid pain management drugs under medicare part d</header><text display-inline="no-display-inline">Section 1860D–4(c) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-104">42 U.S.C. 1395w–104(c)</external-xref>) is amended—</text><paragraph id="HF503A127EA0B48D5BE4EFECFEFE4B316"><enum>(1)</enum><text>by redesignating paragraph (6), as added by section 50354 of division E of the Bipartisan Budget Act of 2018 (<external-xref legal-doc="public-law" parsable-cite="pl/115/123">Public Law 115–123</external-xref>), as paragraph (7); and </text></paragraph><paragraph id="H5CF35A1F822E408795DFE46446ACD911"><enum>(2)</enum><text>by adding at the end the following new paragraph:</text><quoted-block id="H6A26FA45F9964CBF9C9AAEEB2AFF86EF" style="OLC"><paragraph id="H39D96FBA78D74079AF596F1F799A500E"><enum>(8)</enum><header>Prohibition on use of step therapy and prior authorization for qualifying non-opioid pain management drugs</header><subparagraph id="HF8C62CB982864B6C8DE55A9A7EC73271"><enum>(A)</enum><header>In general</header><text>For plan years beginning on or after January 1, 2026, a prescription drug plan or an MA–PD plan may not, with respect to a qualifying non-opioid pain management drug (as defined in section 1860D–2(b)(10)(B)) for which coverage is provided under such plan, impose any—</text><clause id="HC2CC865D0C3E42D2AF3CB465505A9580"><enum>(i)</enum><text>step therapy requirement under which an individual enrolled under such plan is required to use an opioid prior to receiving such drug; or</text></clause><clause id="H872DF9D22E7E482EAE482BD574F5FFAB"><enum>(ii)</enum><text>prior authorization requirement.</text></clause></subparagraph><subparagraph id="HBC2FF3F611B44789B507B0DD187AEE61"><enum>(B)</enum><header>Step therapy</header><text>In this paragraph, the term <quote>step therapy</quote> means a drug therapy utilization management protocol or program that requires use of an alternative, preferred prescription drug or drugs before the plan approves coverage for the non-preferred drug therapy prescribed.</text></subparagraph><subparagraph id="HE683B378D24D4006830413095B23C186"><enum>(C)</enum><header>Prior authorization</header><text>In this paragraph, the term <quote>prior authorization</quote> means any requirement to obtain approval from a prescription drug plan prior to the furnishing of a drug.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section></legis-body></bill> 

